Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Estrella Immunopharma › Armistice Capital, LLC now owns 8.4% of ESLA as a passive investor Fund moves
Why it stands out A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001172661-26-005224
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Nov 2 · filed 2 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Aug 25 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Aug 25 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 17, 2026 Company filing · Form 8-K · Listing notice Received a notice from its stock exchange “On August 17, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), was below $1.00 per share for 30 consecutive business days from July 6, 2026 through August 14,…” Sep 1, 2026 Company filing · Form 8-K · Listing notice Received a notice from its stock exchange “On September 1, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the market value of the Company’s listed securities (“MVLS”) was below $35,000,000 for 30 consecutive business days from July 21, 2026 through August 31, 2026, the Company no longer complies with…” What came next Oct 25, 2026 Company filing · Form 8-K · Executive change, Other news Changed a top executive or board member, and reported other company news “On October 25, 2026, the Board of Directors (the “Board”) of Estrella Immunopharma, Inc. (the “Company”) appointed Cynthia Pussinen, age 57, as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026.” Nov 16, 2026 5% stake Armistice Capital, LLC reported a passive stake (13G) of 8.4%